Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 998

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Role of Systemic Inflammatory Response in Predicting Survival in Patients with Primary Operable Cancer

Roxburgh, Campbell SD, McMillan, Donald C · 2010 · Future Oncology

Abstract

Disease progression in cancer is dependent on the complex interaction between the tumor and the host inflammatory response. There is substantial evidence in advanced cancer that host factors, such as weight loss, poor performance status and the host systemic inflammatory response, are linked, and the latter is an important tumor-stage-independent predictor of outcome. Indeed, the systemic inflammatory response, as evidenced by an elevated level of C-reactive protein, is now included in the definition of cancer cachexia. This review examines the role of the systemic inflammatory response in predicting survival in patients with primary operable cancer. Approximately 80 studies have evaluated the role of the systemic inflammatory response using biochemical or hematological markers, such as elevated C-reactive protein levels, hypoalbuminemia or increased white cell, neutrophil and platelet counts. Combinations of such factors have been used to derive simple inflammation-based prognostic scores, such as the Glasgow Prognostic Score, the neutrophil:lymphocyte ratio and the platelet:lymphocyte ratio. This review demonstrates that there is now good evidence that preoperative measures of the systemic inflammatory response predict cancer survival, independent of tumor stage, in primary operable cancer. The evidence is particularly robust in colorectal (including liver metastases), gastro-esophageal and renal cancers. As described in this article, measurement of the systemic inflammatory response is simple, reliable and can be clinically incorporated into current staging algorithms. This will provide the clinician with a better prediction of outcome, and therefore better treatment allocation in patients with primary operable cancer. Furthermore, systemic inflammation-based markers and prognostic scores not only identify patients at risk, but also provide well-defined therapeutic targets for future clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon.09.136

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 93 references

Research works printed but not linked: 38

  1. 10.1016/0959-8049(94)90417-0 · doi:10.1016/0959-8049(94)90417-0
  2. 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9 · doi:10.1002/1097-0142(19950415)75:8<2077::aid-cncr2820750808>3.0.co;2-9
  3. Wilop S , CrysandtM, BendelM, MahnkenAH, OsiekaR, JostE: Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.Onkologie31(12), 665–670 (2008).
  4. 10.1002/jso.2930360302 · doi:10.1002/jso.2930360302
  5. 10.1016/j.lungcan.2008.04.011 · doi:10.1016/j.lungcan.2008.04.011
  6. 10.1016/S0748-7983(96)92398-7 · doi:10.1016/s0748-7983(96)92398-7
  7. 10.1038/sj.bjc.6604926 · doi:10.1038/sj.bjc.6604926
  8. 10.1038/bjc.1983.198 · doi:10.1038/bjc.1983.198
  9. 10.1111/j.1365-3083.1984.tb00919.x · doi:10.1111/j.1365-3083.1984.tb00919.x
  10. Tartter PI : Pretreatment prognostic factors in colorectal cancer patients with synchronous liver metastases.Eur. J. Surg. Oncol.13(6), 485–491 (1987).
  11. 10.1002/jso.21294 · doi:10.1002/jso.21294
  12. 10.1002/cncr.20976 · doi:10.1002/cncr.20976
  13. 10.3748/wjg.v12.i34.5495 · doi:10.3748/wjg.v12.i34.5495
  14. 10.1016/S0002-9610(01)00684-5 · doi:10.1016/s0002-9610(01)00684-5
  15. 10.1002/jso.10275 · doi:10.1002/jso.10275
  16. 10.1111/j.1442-2050.2005.00474.x · doi:10.1111/j.1442-2050.2005.00474.x
  17. 10.3748/wjg.v12.i23.3746 · doi:10.3748/wjg.v12.i23.3746
  18. 10.1159/000094562 · doi:10.1159/000094562
  19. Suzuki K , AiuraK, KitagouMet al.: Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients.Hepatogastroenterology51(57), 847–853 (2004).
  20. 10.1038/sj.bjc.6602305 · DOI
  21. Menczer J , SchejterE, GevaD, GinathS, ZakutH: Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival.Eur. J. Gynaecol. Oncol.19(1), 82–84 (1998).
  22. 10.1016/S0301-2115(98)00227-9 · doi:10.1016/s0301-2115(98)00227-9
  23. 10.1016/j.ygyno.2003.09.002 · doi:10.1016/j.ygyno.2003.09.002
  24. 10.1016/S0002-9378(94)70225-X · doi:10.1016/s0002-9378(94)70225-x
  25. 10.1159/000093905 · doi:10.1159/000093905
  26. 10.1159/000112601 · doi:10.1159/000112601
  27. 10.1111/j.1464-410X.2007.07408.x · doi:10.1111/j.1464-410x.2007.07408.x
  28. 10.1111/j.1442-2042.1998.tb00380.x · doi:10.1111/j.1442-2042.1998.tb00380.x
  29. 10.1016/S0022-5347(05)64453-9 · doi:10.1016/s0022-5347(05)64453-9
  30. 10.1097/00008469-200206000-00008 · doi:10.1097/00008469-200206000-00008
  31. 10.1016/j.urology.2003.10.039 · doi:10.1016/j.urology.2003.10.039
  32. 10.1111/j.1442-2042.2006.01563.x · doi:10.1111/j.1442-2042.2006.01563.x
  33. 10.1016/S0022-5347(05)00526-4 · doi:10.1016/s0022-5347(05)00526-4
  34. 10.1111/j.1464-410X.2006.06437.x · doi:10.1111/j.1464-410x.2006.06437.x
  35. 10.1111/j.1464-410X.2006.06497.x · doi:10.1111/j.1464-410x.2006.06497.x
  36. 10.1111/j.1464-410X.2007.06934.x · doi:10.1111/j.1464-410x.2007.06934.x
  37. 10.1159/000106322 · doi:10.1159/000106322
  38. 10.1016/j.juro.2008.10.156 · doi:10.1016/j.juro.2008.10.156

Cited by

Metadata

Authors
Roxburgh, C. S., & McMillan, D. C.
Venue
Future Oncology
Published
2009-12-18
Volume
6
Issue
1
Pages
149-163
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2139778116
Cited by
998
References
93
FWCI
12.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.